pCMV-SHP2 WT Citations (14)
Originally described in: SHP2 plasmidsUnpublished
Articles Citing pCMV-SHP2 WT
| Articles |
|---|
| SHP-2 phosphatase activity is required for PECAM-1-dependent cell motility. Zhu JX, Cao G, Williams JT, Delisser HM. Am J Physiol Cell Physiol. 2010 Oct;299(4):C854-65. doi: 10.1152/ajpcell.00436.2009. Epub 2010 Jul 14. PubMed |
| Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity. Fujita Y, Endo S, Takai T, Yamashita T. EMBO J. 2011 Apr 6;30(7):1389-401. doi: 10.1038/emboj.2011.55. Epub 2011 Mar 1. PubMed |
| Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras/extracellular signal-regulated kinase (ERK) pathway. Quintanar-Audelo M, Yusoff P, Sinniah S, Chandramouli S, Guy GR. J Biol Chem. 2011 Jul 1;286(26):23102-12. doi: 10.1074/jbc.M110.212662. Epub 2011 Apr 29. PubMed |
| Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4. Cooke M, Orlando U, Maloberti P, Podesta EJ, Cornejo Maciel F. J Lipid Res. 2011 Nov;52(11):1936-48. doi: 10.1194/jlr.M015552. Epub 2011 Sep 8. PubMed |
| Selective sequestration of STAT1 in the cytoplasm via phosphorylated SHP-2 ameliorates murine experimental colitis. Wu X, Guo W, Wu L, Gu Y, Gu L, Xu S, Wu X, Shen Y, Ke Y, Tan R, Sun Y, Xu Q. J Immunol. 2012 Oct 1;189(7):3497-507. Epub 2012 Aug 31. PubMed |
| Src homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytes. Mamik MK, Ghorpade A. PLoS One. 2012;7(9):e45596. doi: 10.1371/journal.pone.0045596. Epub 2012 Sep 21. PubMed |
| MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells. Beigbeder A, Chartier FJM, Bisson N. Sci Rep. 2017 Sep 14;7(1):11514. doi: 10.1038/s41598-017-11876-9. PubMed |
| Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis. Guo W, Liu W, Chen Z, Gu Y, Peng S, Shen L, Shen Y, Wang X, Feng GS, Sun Y, Xu Q. Nat Commun. 2017 Dec 18;8(1):2168. doi: 10.1038/s41467-017-02351-0. PubMed |
| Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D, Gorgulu K, Dantes Z, Wormann SM, Diakopoulos KN, Karpathaki AF, Kowalska M, Kaya-Aksoy E, Song L, van der Laan EAZ, Lopez-Alberca MP, Nazare M, Reichert M, Saur D, Erkan MM, Hopt UT, Sainz B Jr, Birchmeier W, Schmid RM, Lesina M, Algul H. Nat Med. 2018 Jul;24(7):954-960. doi: 10.1038/s41591-018-0024-8. Epub 2018 May 28. PubMed |
| Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. LaRochelle JR, Fodor M, Vemulapalli V, Mohseni M, Wang P, Stams T, LaMarche MJ, Chopra R, Acker MG, Blacklow SC. Nat Commun. 2018 Oct 30;9(1):4508. doi: 10.1038/s41467-018-06823-9. PubMed |
| Shp2-mediated MAPK pathway regulates DeltaNp63 in epithelium to promote corneal innervation and homeostasis. Okada Y, Zhang Y, Zhang L, Yeh LK, Wang YC, Saika S, Liu CY. Lab Invest. 2019 Oct 25. pii: 10.1038/s41374-019-0338-2. doi: 10.1038/s41374-019-0338-2. PubMed |
| Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. Vemulapalli V, Chylek LA, Erickson A, Pfeiffer A, Gabriel KH, LaRochelle J, Subramanian K, Cao R, Stegmaier K, Mohseni M, LaMarche MJ, Acker MG, Sorger PK, Gygi SP, Blacklow SC. Elife. 2021 Mar 23;10. pii: 64251. doi: 10.7554/eLife.64251. PubMed |
| Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state. Lin CC, Suen KM, Jeffrey PA, Wieteska L, Lidster JA, Bao P, Curd AP, Stainthorp A, Seiler C, Koss H, Miska E, Ahmed Z, Evans SD, Molina-Paris C, Ladbury JE. Mol Cell. 2022 Mar 17;82(6):1089-1106.e12. doi: 10.1016/j.molcel.2022.02.005. Epub 2022 Feb 28. PubMed |
| Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. Heynen GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E, Marangoni E, Birchmeier W. Breast Cancer Res. 2022 Apr 1;24(1):23. doi: 10.1186/s13058-022-01521-3. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.